CMBA
ADCT icon

C.M. Bidwell & Associates’s ADC Therapeutics ADCT Stock Holding History

C.M. Bidwell & Associates’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,119
Closed -$4.2K – 495
2026
Q1 		$4.2K Buy
+1,119
New +$4.41K ﹤0.01% 344

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

C.M. Bidwell & Associates's ADCT Position: Q2 2026 in Review

C.M. Bidwell & Associates sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 1,119 shares — an estimated $4.2K sold.

C.M. Bidwell & Associates first reported a position in ADCT in Q1 2026 and held it in 1 quarter. The position peaked at $4.2K in Q1 2026. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • C.M. Bidwell & Associates reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 1,119 ADC Therapeutics shares in Q2 2026, an estimated $4.2K.
  • C.M. Bidwell & Associates first reported a position in ADC Therapeutics in Q1 2026 and held it in 1 quarter.
  • C.M. Bidwell & Associates's ADC Therapeutics position peaked at $4.2K in Q1 2026.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.